Explore MK-677 and ibutamoren research, growth-hormone signaling, clinical studies, safety findings, and comparisons with peptide secretagogues.
MK-677, also called ibutamoren, is a nonpeptide growth-hormone secretagogue. It belongs in a research-compound directory but should not be described as a peptide or a SARM.
Ibutamoren is a small molecule; peptide secretagogues such as ipamorelin have different structures. A shared growth-hormone endpoint does not make the compounds equivalent.
It activates the ghrelin receptor and has been studied for effects on growth hormone and IGF-1. Changes in these markers are not proof of better physical function or long-term clinical benefit.
Human trials have examined body composition, endocrine responses, and disease-specific outcomes. In a randomized study of healthy older adults, fat-free mass increased without demonstrated improvements in strength or function; glucose-related findings were a limitation.
FDA identifies ibutamoren as an unapproved active ingredient and has highlighted safety concerns. Research reports do not establish approval or safety of retail products. This topic provides evidence interpretation, not administration instructions.
Ibutamoren is a nonpeptide ghrelin mimetic. A randomized trial in healthy older adults found changes in growth-hormone signaling and fat-free mass, but did not demonstrate improved strength or physical function. Biomarker and body-composition findings should be read separately from clinical benefit. Randomized trial, PMID 18981485
FDA describes ibutamoren, also known as MK-677, as an active ingredient that is not approved by the agency. Its safety notice identifies fluid retention and glucose-related concerns, among other potential harms; this is not evidence for a safe research-market formulation. FDA safety notification
Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.
Growth Hormone Deficiency (GHD)
Loti Labs MK-677 is sold as a research chemical, not a supplement. Learn about purity checks, pricing, legal status, and safety before you buy.
Ipamorelin vs MK-677: how these two growth hormone secretagogues differ in form, dosing, side effects, appetite, and legal status in the United States.
Evolution Peptides MK 677 is sold as a research chemical, not a supplement. Learn what MK-677 does, how to vet vendors, and the safety and legal risks.
CJC 1295 ipamorelin vs MK 677: compare how these two GH-boosting options differ in delivery, dosing, regulation, and side effect profiles in the US.
MK-677 vs CJC-1295 compared: how the oral ghrelin agonist differs from the injectable GHRH analog in half-life, dosing, side effects, and legal status.
MK-677 vs sermorelin: compare how an oral ghrelin agonist and an injectable GHRH peptide raise growth hormone, plus side effects, legality, and dosing.
CJC 1295 vs MK 677: compare the injectable peptide and oral GH secretagogue. Learn how they differ in half-life, side effects, and legal status.
MK-677 vs tesamorelin compared: how each raises GH and IGF-1, dosing, side effects, FDA status, and which option fits fat loss or research goals.
CJC-1295 DAC vs MK-677: compare how these two growth hormone boosters work, their side effects, legal status, and which one researchers study more.
Tesamorelin vs MK-677 compared: how each works, FDA approval status, dosing, side effects, and what they can and cannot do. Read this before you choose.
MK 677 vs CJC 1295: compare oral ghrelin agonists and injectable GHRH analogs, their half-lives, GH release patterns, side effects, and FDA status.
Sermorelin vs MK 677 Reddit debates compare injectable peptides and oral secretagogues. Learn how they differ in their mechanism, side effects, and results.